Using Protease Tag® Technology, ProAxsis develops and supplies diagnostic assays focusing on respiratory biomarkers, improving the lives of patients suffering from a variety of chronic respiratory diseases.
The ProteaseTag® is the foundation on which ProAxsis has developed its business.
ProteaseTags® are smart molecules that irreversibly bind to the active site of a target protease and form a bridge to a solid support, allowing them to be incorporated in to established platforms such as ELISA and lateral flow devices.
ProteaseTags® enable the detection of risk factors before an exacerbation, providing a crucial opportunity for intervention before the need for secondary care.
ProAxsis’ immunoassays and point-of-care tests incorporate a ProteaseTag®, patented technology for the rapid detection of active protease biomarkers of disease.
ProAxsis has developed a range of Assays incorporating patented technology, including:
ProAxsis offer a range of contract services from protease biomarker investigation, clinical trial and pharma services to academic support services:
ProAxsis products aide the treatment of diseases associated with breathlessness, persistent cough and chronic lung function decline, such as:
Interested in learning more? Get in touch.